Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3035% below fair value
$10.92−0.45 (-3.96%)
Close on Nov 16, 2026Market cap $667.61MP/E –Yield –
Janux Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Janux Therapeutics
Janux Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?